Table 2.
Killer Cell Immunoglobulin-like Receptors and Ligand Prevalence
| Ligand | Participants With Ligand, % (N = 890)a |
|---|---|
| KIR ligands | |
| KIR2DL1 (n = 888) | 98.6 |
| KIR2DL2 | 54.7 |
| KIR2DL3 (n = 883) | 84.8 |
| KIR2DL4 | 99.7 |
| KIR2DL5 | 57.9 |
| KIR2DP1 | 98.1 |
| KIR2DS1 | 23.5 |
| KIR2DS2 | 49.0 |
| KIR2DS3 | 23.0 |
| KIR2DS4 | 68.3 |
| KIR2DS5 | 42.6 |
| KIR3DL1 | 98.7 |
| KIR3DL2 | 99.6 |
| KIR3DS1 | 13.0 |
| HLA ligands | |
| C1/C2 ligand group zygosity (n = 889) | |
| C1/C1 | 19.5 |
| C1/C2 | 53.1 |
| C2/C2 | 27.4 |
| Bw4 ligand group (≥1 copy) | 74.8 |
Abbreviation: KIR, Killer cell immunoglobulin-like receptor.
aN = 890 except where otherwise noted; numbers were reduced for some ligands and KIR owing to failed amplification or lack of DNA.